InterCure Reports H1 2025 Results: NIS 130M Revenue

Ticker: INCR · Form: 6-K · Filed: Oct 8, 2025 · CIK: 1857030

Intercure Ltd. 6-K Filing Summary
FieldDetail
CompanyIntercure Ltd. (INCR)
Form Type6-K
Filed DateOct 8, 2025
Risk Levelmedium
Pages1
Reading Time2 min
Sentimentneutral

Sentiment: neutral

Topics: financial-results, revenue, cash-flow

TL;DR

InterCure hit NIS 130M revenue in H1 2025, showing positive cash flow.

AI Summary

InterCure Ltd. reported its first half 2025 results on October 8, 2025, with revenues reaching NIS 130 million and positive operating cash flow. The company filed a Form 6-K, including a press release and condensed consolidated unaudited interim financial statements as of June 30, 2025.

Why It Matters

This filing provides investors with InterCure's recent financial performance, indicating revenue growth and positive cash flow, which are key metrics for assessing the company's operational health.

Risk Assessment

Risk Level: medium — The filing contains financial results, which are standard for public companies, but the specific performance and market conditions can introduce medium-level risk.

Key Numbers

  • NIS 130 Million — Revenue (First half 2025 revenue reported)

Key Players & Entities

  • Intercure Ltd. (company) — Registrant
  • NIS 130 Million (dollar_amount) — First half 2025 revenue
  • October 8, 2025 (date) — Date of press release and filing
  • June 30, 2025 (date) — Date of financial statements

FAQ

What was InterCure Ltd.'s revenue for the first half of 2025?

InterCure Ltd. reported NIS 130 million in revenue for the first half of 2025.

What type of financial statements were included in the 6-K filing?

The filing included Condensed Consolidated Unaudited Interim Financial Statements as of June 30, 2025.

On what date was the press release regarding the first half 2025 results issued?

The press release was issued on October 8, 2025.

What is the company's principal executive office address?

The principal executive offices are located at 85 Medinat ha-Yehudim Street, Herzliya, 4676670, Israel.

Does InterCure Ltd. file annual reports under Form 20-F or 40-F?

InterCure Ltd. files annual reports under Form 20-F.

Filing Stats: 397 words · 2 min read · ~1 pages · Grade level 12.4 · Accepted 2025-10-08 08:50:10

Filing Documents

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. INTERCURE LTD. Date: October 8, 2025 /s/ Amos Cohen Amos Cohen Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.